Uso do icatibanto em gestante com AEH-FXII: relato de caso
Icatibant in a pregnant woman with HAE-FXII: a case report
Caroline Rosa Emergente Coutinho; Daniel Carlos Santos Macedo; Erika P. Souza; Larissa Oliveira F. Silva Lima; Adriana Santos Moreno; Marina M. Dias; Luisa Karla Arruda; Eli Mansour
Resumo
O angioedema hereditário (AEH) por variantes patogênicas no gene que codifica o Fator XII da coagulação (AEHFXII) é o tipo mais comum de AEH com inibidor de C1 normal (AEH-nC1NH). O AEH-FXII é altamente influenciado pela exposição ao estrogênio. Pacientes com esta condição tendem a ter piora do angioedema em períodos de elevação deste hormônio, como na gestação. Atualmente, não há tratamentos específicos aprovados para o manejo do AEH-FXII, e durante a gravidez o tratamento pode ser ainda mais desafiador, visto que os medicamentos recomendados como primeira linha nem sempre estão disponíveis. Neste relato, descrevemos o caso de uma gestante portadora de AEH-FXII que recebeu icatibanto em dose única durante crise de angioedema de vias aéreas superiores no terceiro trimestre, com desfecho favorável para a paciente e para o feto.
Palavras-chave
Abstract
Hereditary angioedema (HAE) due to pathogenic variants in the factor XII gene (HAE-FXII) is the most common type of HAE with normal C1 inhibitor (HAE-nC1INH). HAE-FXII is highly influenced by estrogen exposure. Patients with this condition tend to experience worsening of angioedema-related symptoms during periods of elevated estrogen, such as pregnancy. Currently, there is no approved treatment for HAE-FXII, and during pregnancy management can be even more challenging, since first-line drugs are not always available. We report the case of a pregnant woman with HAE-FXII who received a single dose of icatibant during an upper airway angioedema attack in the third trimester, with a favorable outcome for the patient and fetus.
Keywords
Referências
1. Campos RA, Serpa FS, Mansour E, Alonso MLO, Arruda LK, Aun MV, et al. Diretrizes brasileiras do angioedema hereditário 2022 - Parte 1: definição, classificação e diagnóstico. Arq Asma Alerg Imunol. 2022;6(2):151-69.
2. Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, AygörenPürsün E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update. Allergy. 2022. doi:10.1111/all.15214.
3. Gutierrez M, Veronez CL, Rodrigues Valle SO, Gonçalves RF, Ferriani MPL, Moreno AS, et al. Unnecessary Abdominal Surgeries in Attacks of Hereditary Angioedema with Normal C1 Inhibitor. Clin Rev Allergy Immunol. 2021;61:60-5. 4. Dias MM, Moreno AS, Maia LSM, Nunes FL, Campos WN, Ferriani MPL, et al. A cost-effective algorithm for diagnosis of hereditary angioedema with normal C1 inhibitor: Applying molecular approach to clinical practice. The Journal of Allergy and Clinical Immunology: In Practice. 2020;8:419-421.e4.
5. Arruda LK, Ferriani MPL. Treatment of hereditary angioedema: When the goal is having a normal life. J Allergy Clin Immunol. 2021;148:80‑2.
6. Cohn DM, Arruda LK. Preventing Deaths from Angioedema: It’s Time to Look Ahead. J Allergy Clin Immunol Pract. 2020;8:1775‑6.
7. Campos RA, Serpa FS, Mansour E, Alonso MLO, Arruda LK, Aun MV, et al. Diretrizes brasileiras de angioedema hereditário 2022 - Parte 2: terapêutica. Arq Asma Alerg Imunol. 2022;6(2):170‑96.
8. Garcia JFB, Takejima P, Veronez CL, Aun MV, Motta AA, Kalil J, et al. Use of pdC1-INH concentrate for long-term prophylaxis during pregnancy in hereditary angioedema with normal C1-INH. J Allergy Clin Immunol Pract. 2018;6:1406‑8.
9. Bork K, Machnig T, Wulff K, Witzke G, Prusty S, Hardt J. Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence. Orphanet J Rare Dis. 2020;15:289.
10. Veronez CL, Moreno AS, Constantino-Silva RN, Maia LSM, Ferriani MPL, Castro FFM, et al. Hereditary Angioedema with Normal C1 Inhibitor and F12 Mutations in 42 Brazilian Families. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6:1209‑16. e8.
11. Loli-Ausejo D, Hernández-Martín I, Cabañas R, Entrala A, GutiérrezAlvariño M, Martínez-Sánchez N, et al. Tranexamic Acid Plus Bemiparin Sodium as Long- Term Prophylaxis in a Patient With FXII-HAE During Pregnancy: A Case Report. J Investig Allergol Clin Immunol. 2020;30:464‑5.
12. Gabriel N, Marcelino F, Ferriani MPL, Arruda LK, Campos RA, Gonçalves RF, et al. Pregnancy in Patients With Hereditary Angioedema and Normal C1 Inhibitor. Front Allergy. 2022;3:846968.
13. Šimac DV, Štimac T, Novak S. Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy? Curr Allergy Asthma Rep. 2022;22:135-40.
14. Riedl MA. Hereditary Angioedema During Pregnancy: Considerations in Management. Immunol Allergy Clin North Am. 2023;43(1):145‑57.
15. Kaminsky LW, Kelbel T, Ansary F, Craig T. Multiple doses of icatibant used during pregnancy. Allergy Rhinol (Providence). 2017;8:178‑81.
16. Gompel A, Fain O, Boccon-Gibod I, Gobert D, Bouillet L. Exogenous hormones and hereditary angioedema. Int Immunopharmacol. 2020;78:106080.
17. Jones D, Zafra H, Anderson J. Managing Diagnosis, Treatment, and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor. JAA. 2023;16:447‑60.
18. Chong-Neto HJ, Aroni BP, Mansour E, Toledo E, Serpa FS, Arruda LK, et al. Are pediatricians familiar with hereditary angioedema? World Allergy Organ J. 2023 Jun 10;16(6):100783
Submetido em:
25/04/2024
Aceito em:
30/06/2024
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email